Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial of sugammadex versus neostigmine for postoperative pulmonary complications
ACTRN12620001313921Phase 4Completed
- Sponsor
- Melbourne Health
- Start
- Jan 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of Sugammadex and neostigmine in postoperative respiratory complications (PRC), sponsored by Melbourne Health. Primary endpoint: Rate of recruitment of eligible patients who were approached for consent to participate. Started Jan 2021; status: completed.
02
Drugs
Sugammadexneostigmine
03
Conditions
postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ACTRN12620001313921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001313921.